18/08/2026 17:05

Cochlear (ASX: COH) $141.20

COH +7.58%: Delivered a better-than-expected FY26 result with profit comfortably ahead of consensus despite broadly flat revenue. FY27 guidance points to earnings growth resuming as margins recover, although management remains cautious on the top line with only low-single-digit sales growth expected. 

Read more

25/06/2026 09:20

Cochlear Ltd (ASX: COH) $113.45

COH has delivered two painful downgrades in 2026, taking the stock down 56% just this year. We covered Aprils savage downgrade here, coming to the easy conclusion that this was a stock best avoided for the foreseeable future, especially if we remember the market adage, “Buy the Third Downgrade.” Two downgrades in three months do not breed confidence in a market that’s very comfortable throwing stocks into the naughty corner and forgetting about them.

Read more

23/04/2026 09:17

Cochlear Ltd (ASX:COH) $99.58

We covered the Cochlear dramatic downgrade in detail yesterday Here. As we said at the time, COH was whacked after delivering one of the ugliest downgrades in a long time, especially when it was only two months ago that they said earnings would likely be at the lower end of guidance, not 30% below! - credibility straight out of the window.

Read more

22/04/2026 17:34

Cochlear (ASX:COH) $99.58

COH -40.7%: was whacked today after delivering one of the ugliest downgrades we’ve seen from a large cap healthcare name in some time. The hearing implant leader slashed FY26 underlying net profit guidance to $290–330m, down from the previous $435–460m range, with the stock plunging 40% on the day - its worst sell-off since listing.

Read more

22/04/2026 10:45

Cochlear Ltd (ASX:COH) $104.50

Cochlear (ASX:COH) has plunged almost 40%, the most in more than 30-years,after downgrading net profit guidance by ~25%.

Read more

11/03/2026 09:20

Cochlear Ltd (COH) $182.52

COH has more than halved from its 2024 high, and it now trades on its lowest valuation of the decade, despite revenue continuing to climb from $1.6bn in 2022 to a forecast $2.7bn by 2027. However, the market showed little patience during the recent reporting season, with the hearing device maker falling ~25% in February after a comparatively modest ~5% 1H profit miss.

Read more

04/11/2025 09:26

Cochlear Ltd (COH) $283.89

At the end of October, COH reaffirmed its FY26 earnings guidance, for an 11% to 17% increase in underlying net profit from last year. Device demand across both cochlear implants and Acoustics looks strong, while Services expectations have been reset over the last 12-18 months, which puts the stock firmly in the “buy the dip” camp for MM.

Read more

16/09/2025 09:42

Cochlear Ltd (COH) $302.72

COH had a quiet report last month after flagging much of the result in June which at the time saw the stock surge back towards $300. The company is pinning its hopes on the rollout of a new hearing implant called Nucleus Nexa to boost earnings after this year’s disappointing performance, although net profit still grew 9%.

Read more

08/07/2025 09:35

Cochlear Ltd (COH) $300.74

COH surged higher in June ironically after headlines of “Cochlear cuts guidance”. The hearing company flagged an underlying net profit for the 12 months through June of $390-400mn, down by around 6% compared to its February numbers.

Read more

13/02/2025 09:29

Cochlear Ltd (COH) $306.69

Hearing implant business COH was the best-performing healthcare name on Wednesday, closing up +1.6%. However, we remain concerned that the share price isn’t factoring in the risks of Moderna’s potential phase III data for a vaccine against human cytomegalovirus, which causes infant deafness.

Read more